Crizotinib in ALK-positive lung cancer

被引：4
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [21] Anaplastic large cell lymphoma, ALK-positive
    Ferreri, Andres J. M.
    Govi, Silvia
    Pileri, Stefano A.
    Savage, Kerry J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (02) : 293 - 302
  • [22] Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
    Shrestha, N.
    Nimick, M.
    Dass, P.
    Rosengren, R. J.
    Ashton, J. C.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript
    Wang, Wei-ya
    Gu, Ling
    Liu, Wei-ping
    Li, Gan-di
    Liu, Hua-jun
    Ma, Zhi-gui
    PATHOLOGY RESEARCH AND PRACTICE, 2011, 207 (09) : 587 - 591
  • [24] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [25] Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors
    Trahair, Toby
    Gifford, Andrew J.
    Fordham, Ashleigh
    Mayoh, Chelsea
    Fadia, Mitali
    Lukeis, Robyn
    Wood, Andrew C.
    Valvi, Santosh
    Walker, Roderick D.
    Blackburn, James
    Heyer, Erin E.
    Mercer, Tim R.
    Barbaric, Draga
    Marshall, Glenn M.
    MacKenzie, Karen L.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11
  • [26] Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
    Zhou, Yuhang
    Hurtado-Castillo, Marisabel
    Pandey, Om
    FRONTIERS IN MEDICINE, 2023, 10
  • [27] Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
    Wu, Yi-Long
    Lu, Shun
    Lu, You
    Zhou, Jianying
    Shi, Yuan-kai
    Sriuranpong, Virote
    Ho, James C. M.
    Ong, Choo Khoon
    Tsai, Chun-Ming
    Chung, Chin-Hee
    Wilner, Keith D.
    Tang, Yiyun
    Masters, Elizabeth T.
    Selaru, Paulina
    Mok, Tony S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1539 - 1548
  • [28] The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
    Rajan, Soumya S.
    Amin, Amit Dipak
    Li, Lingxiao
    Rolland, Delphine C.
    Li, Haiquan
    Kwon, Deukwoo
    Kweh, Mercedes F.
    Arumov, Artavazd
    Roberts, Evan R.
    Yan, Aimin
    Basrur, Venkatesha
    Elenitoba-Johnson, Kojo S. J.
    Chen, Xi Steven
    Puvvada, Soham D.
    Lussier, Yves A.
    Bilbao, Daniel
    Lim, Megan S.
    Schatz, Jonathan H.
    ONCOGENE, 2020, 39 (10) : 2103 - 2117
  • [29] Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer
    Song, Qi
    Li, Jie
    Xiong, Qi
    Long, Ya Ping
    Yang, Bo
    Dong, Zhou Huan
    Liang, Chao Yang
    Yang, Bo
    IMMUNOTHERAPY, 2023, 15 (11) : 809 - 817
  • [30] Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
    Passaro, Antonio
    Lazzari, Chiara
    Karachaliou, Niki
    Spitaleri, Gianluca
    Pochesci, Alessia
    Catania, Chiara
    Rosell, Rafael
    de Marinis, Filippo
    ONCOTARGETS AND THERAPY, 2016, 9 : 6361 - 6376
12345